AVE1642
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for AVE1642, covering 2010-08-04 to 2011-03-03. Get the full timeline:
Most recent: Clinical Trial Update: Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer [Phase 2]